EGFR and cancer: Applying the concept of the cancer-immunity cycle in this study allowed us to reveal the potential mechanisms of non-responsiveness to ICI relying on low immunogenicity of tumors with altered ALK and EGFR. Most of them demonstrated ID or IE TME reflecting the inefficiency of primary tumor cell recognition.